ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

AVTE Aerovate Therapeutics Inc

20.74
0.83 (4.17%)
After Hours
Last Updated: 18:00:01
Delayed by 15 minutes

Period:

Draw Mode:

Volume 459,757
Bid Price 19.00
Ask Price 32.98
News (1)
Day High 21.335

Low
9.41

52 Week Range

High
32.415

Day Low 19.34
Share Name Share Symbol Market Stock Type
Aerovate Therapeutics Inc AVTE NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
0.83 4.17% 20.74 18:00:01
Open Price Low Price High Price Close Price Previous Close
19.34 19.34 21.335 20.74 19.91
Trades Shares Traded VWAP Financial Volume Average Volume 52 Week Range
6,389 459,757 US$ 20.38 US$ 9,370,922 - 9.41 - 32.415
Last Trade Type Quantity Price Currency
15:14:20 18 US$ 20.79 USD

Aerovate Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
573.3M 27.67M - 0 -75.52M -2.73 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Aerovate Therapeutics News

Date Time Source News Article
6/07/202416:00Edgar (US Regulatory)Form 8-K - Current report
5/21/202415:15GlobeNewswire Inc.Aerovate Therapeutics Presents Baseline Data from the Phase..
5/17/202418:10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
5/17/202415:59Edgar (US Regulatory)Form 144 - Report of proposed sale of securities
5/13/202415:57Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]
5/13/202415:39Edgar (US Regulatory)Form 8-K - Current report
5/13/202415:30GlobeNewswire Inc.Aerovate Therapeutics Announces First Quarter Financial..
3/27/202408:20GlobeNewswire Inc.Aerovate Therapeutics to Present Patient Baseline..
3/25/202415:10GlobeNewswire Inc.Aerovate Therapeutics Announces Full-Year 2023 Financial..
3/11/202417:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
3/07/202415:37Edgar (US Regulatory)Form 144 - Report of proposed sale of securities
3/06/202407:00GlobeNewswire Inc.Aerovate Therapeutics Board of Directors Appoints Habib..
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No AVTE Message Board. Create One! See More Posts on AVTE Message Board See More Message Board Posts

Historical AVTE Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week17.8021.33515.7618.34352,9762.9416.52%
1 Month21.6822.4815.5218.71256,807-0.94-4.34%
3 Months24.4132.41515.5222.57201,892-3.67-15.03%
6 Months16.4032.41515.5221.78146,1394.3426.46%
1 Year16.3032.4159.4119.25112,9604.4427.24%
3 Years28.0032.4157.7418.60102,750-7.26-25.93%
5 Years28.0032.4157.7418.60102,750-7.26-25.93%

Aerovate Therapeutics Description

Aerovate Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease. Its initial focus is on advancing AV-101, dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, a devastating disease impacting people in the United States and Europe.